Data on the endogenous conversion of tyrosol into hydroxytyrosol in humans

Anna Boronat; Julian Mateus; Natalia Soldevila-Domenech; Mercè Guerra; Jose Rodríguez-Morató; Carlota Varon; Daniel Muñoz; Francina Barbosa; Juan Carlos Morales; Andreas Gaedigk; Klaus Langohr; Maria-Isabel Covas; Clara Pérez-Mañá; Montserrat Fitó; Rachel F Tyndale; Rafael de la Torre

doi:10.1016/j.dib.2019.104787

Data on the endogenous conversion of tyrosol into hydroxytyrosol in humans

Data Brief. 2019 Nov 12:27:104787. doi: 10.1016/j.dib.2019.104787. eCollection 2019 Dec.

Authors

Anna Boronat^{1

2}, Julian Mateus¹, Natalia Soldevila-Domenech^{1

2}, Mercè Guerra², Jose Rodríguez-Morató², Carlota Varon³, Daniel Muñoz^{4

5}, Francina Barbosa⁶, Juan Carlos Morales⁷, Andreas Gaedigk⁸, Klaus Langohr^{1

9}, Maria-Isabel Covas^{4

10}, Clara Pérez-Mañá^{11

12}, Montserrat Fitó^{4

5}, Rachel F Tyndale¹³, Rafael de la Torre^{1

2

5}

Affiliations

¹ Integrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research Program, IMIM-Institut Hospital del Mar d'Investigacions Mèdiques, Dr. Aiguader 88, 08003, Barcelona, Spain.
² Department of Experimental and Health Sciences, Universitat Pompeu Fabra (CEXS-UPF), Dr. Aiguader 80, 08003, Barcelona, Spain.
³ Department of Pharmacy, Vall d'Hebron Barcelona Hospital Campus, Passeig de Vall d'Hebron 119-129, 08035, Barcelona, Spain.
⁴ Cardiovascular Risk and Nutrition Research Group, IMIM (Hospital del Mar Research Institute), Dr. Aiguader 88, 08003, Barcelona, Spain.
⁵ CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN, CB06/03/028), Monforte de Lemos 3-5, 28029, Madrid, Spain.
⁶ CAP Barceloneta, Parc Sanitari Rovira Virgili, Passeig Marítim, 25 08003, Barcelona, Spain.
⁷ Department of Biochemistry and Molecular Pharmacology, Instituto de Parasitología y Biomedicina López Neyra, CSIC, PTS Granada, Avda. del Conocimiento, 17, 18016, Armilla, Granada, Spain.
⁸ Division of Clinical Pharmacology, Toxicology, and Therapeutic Innovation, Children's Mercy Kansas City, Kansas City, MO, USA.
⁹ Department of Statistics and Operations Research, Polytechnic University of Catalonia, Barcelona, Spain.
¹⁰ NUPROAS Handesbolag (NUPROAS HB), Nacka, Sweden.
¹¹ School of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain.
¹² Hospital Universitari Germans Trias i Pujol (IGTP), Badalona, Spain.
¹³ Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Departments of Pharmacology & Toxicology, and Psychiatry, University of Toronto, 1 King's College Circle, Toronto, ON M5S 1A8, Canada.

Abstract

Here we present new and original data on the endogenous conversion of tyrosol (Tyr) into hydroxytyrosol (OHTyr) in humans and its effects on the cardiovascular system. A randomized, crossover, controlled clinical trial was performed with individuals at cardiovascular risk (n = 33). They received white wine (WW) (females 1, males 2 standard drinks/day), WW plus Tyr capsules (WW + Tyr) (25mg Tyr capsule, one per WW drink), and water (control) ad libitum. Intervention periods were of 4 weeks preceded by three-week wash-out periods. We assessed the conversion of Tyr to OHTyr, its interaction with a polygenic activity score (PAS) from CYP2A6 and CYP2D6 genotypes, and the effects on cardiovascular risk markers. For further details and experimental findings please refer to the article "Cardiovascular benefits of tyrosol and its endogenous conversion into hydroxytyrosol in humans. A randomized, controlled trial" [1].

Keywords: CYP2A6; CYP2D6; Cardiovascular risk; Endogenous conversion; Hydroxytyrosol; Tyrosol.